EGFR and non-small cell lung carcinoma: The emerging role of CD39/CD73 - adenosine axis in EGFR-mutated NSCLC growth, progression, and ICI resistance has allowed to define a further immune checkpoint as a potential strategy to develop targeted treatments (79, 80).